Green Cross Watchlist
Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback
214 Views, 15 Jan 2022 23:01
Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
- The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
- Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.